Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that it has received a letter of intent from its animal health partner. The purpose of this letter of intent is to guarantee both parties' rights, confirming the discussions currently underway leading to the signing of the final agreement.
In parallel, Quantum Genomics and its partner, a major player in the animal health field, are continuing their efforts to jointly define the outlines and protocol of the next clinical trials with the intention to market a future animal health drug.
Their collaboration began in February 2014 with the research program for QGC101, a drug candidate for the prevention and treatment of heart failure in animals.
- From 11th to 14th January 2016 : JP Morgan Healthcare Conference in San Francisco
- January 27th, 2016 : Invest Securities BioMed Event in Paris
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (isin code FR0011648971, Ticker ALQGC).
Twitter : @QuantumGenomics - LinkedIn : Quantum Genomics
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
|ACTUS finance & communication
+33 1 53 67 36 73